Pasithea

Pasithea logo
  • Pipeline
  • Our Team
    • Leadership
    • Advisory Board
  • Investors
  • News
  • Contact
Menu
  • Pipeline
  • Our Team
    • Leadership
    • Advisory Board
  • Investors
  • News
  • Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
May 28, 2024 6:59am EDT

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Apr 29, 2024 7:59am EDT

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 24, 2024 7:59am EDT

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Feb 13, 2024 7:59am EST

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Jan 08, 2024 7:59am EST

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 02, 2024 8:35am EST

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Dec 28, 2023 5:00pm EST

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 19, 2023 5:19pm EST

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 11, 2023 8:01am EST

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Nov 29, 2023 4:27pm EST

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Pasithea logo

Menu

  • About
  • Pipeline
  • Leadership
  • Advisory Board
  • Clinics
  • Investors
  • News
  • Contact

Contact

  • info@pasithea.com
  • +1 786-977-3380
  • 1111 Lincoln Road,
    Suite 500,
    Miami Beach,
    FL 33139

Social Media

Twitter
Facebook-f
Instagram
Linkedin

© Pasithea Therapeutics all rights reserved

Privacy Policy

Terms of use

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
ACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie Duration Description
cookielawinfo-checbox-analytics 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional 11 months The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary 11 months This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance 11 months This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy 11 months The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Performance

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Advertisement

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

Others

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

Save & Accept